HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boudoulas, H. Articles by Vasko, J. S. Search for Related Content PubMed PubMed Citation Articles by Boudoulas, H. Articles by Vasko, J. S.

The Annals of Thoracic Surgery, Vol 26, 222-227, Copyright © 1978 by The Society of Thoracic Surgeons

ARTICLES

Safety and rationale for continuation of propranolol therapy during coronary bypass operation

H Boudoulas, GL Snyder, RP Lewis, RE Kates, PE Karayannacos and JS Vasko

Thirty consecutive patients undergoing coronary bypass were studied. Oral propranolol therapy was maintained up to 4 to 10 hours before operation. Nineteen of the patients had a history of myocardial infarction (MI), 14 had hypoakinetic areas, and 8 had decreased ejection fraction indicating advanced coronary artery disease. Twenty- four-hour urinary epinephrine and norepinephrine obtained the day before operation were markedly increased at 136 +/- 12 microgram per 24 hours (normal, 39 +/- 4 microgram, rho less than 0.01). There were 4 perioperative MIs (13%) and no deaths. Plasma propranolol 1 hour before operation was 43.3 +/- 8 ng per milliliter, indicating good beta blockade. Propranolol was started within 24 hours postoperatively. There were no preoperative, intraoperative, or postoperative complications related to propranolol therapy. We conclude that because of markedly increased adrenergic tone the day before operation and transient hypersensitivity to adrenergic stimulation after withdrawal of propranolol, this agent should be continued through coronary bypass operation.

This article has been cited by other articles:

				M. Budeus, P. Feindt, E. Gams, H. Wieneke, S. Sack, R. Erbel, and C. Perings {beta}-Blocker Prophylaxis for Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Sympathovagal Imbalance Ann. Thorac. Surg., July 1, 2007; 84(1): 61 - 66. [Abstract] [Full Text] [PDF]

				F. Toraman, E. H. Karabulut, H. C. Alhan, S. Dagdelen, and S. Tarcan Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting Ann. Thorac. Surg., October 1, 2001; 72(4): 1256 - 1262. [Abstract] [Full Text] [PDF]

				C. W. Hogue Jr and M. L. Hyder Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment Ann. Thorac. Surg., January 1, 2000; 69(1): 300 - 306. [Abstract] [Full Text] [PDF]

				M. Nordlander, M. Pfaffendorf, and H. B. van Wezel Calcium Antagonists for Perioperative Blood Pressure Control Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 231 - 242. [Abstract] [PDF]

				B. N. Singh, B. Lopez, and J. S.M. Sarma Significance and Prevention of Atrial Fibrillation Occurring After Cardiac Surgery: A Time for Fundamental Change in Strategy? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(3): 259 - 267. [PDF]

				J. M. Kalman, M. Munawar, L. G. Howes, W. J. Louis, B. F. Buxton, G. Gutteridge, and A. M. Tonkin Atrial Fibrillation After Coronary Artery Bypass Grafting Is Associated With Sympathetic Activation Ann. Thorac. Surg., December 1, 1995; 60(6): 1709 - 1715. [Abstract] [Full Text]